Fig. 4: CDKN1A as an ARGOS gene.

a The map of copy number alterations in chromosome 6 shows a p-arm amplification, where CDKN1A is located among other known oncogenes. Amplifications (red) and deletions (blue) are shown for this genomic region. The genomic location of OGs and TSGs are shown at the level of amplification- and deletion frequencies for easier visibility, reflecting their respective selection pressure. b Compensation scores for CDKN1A in our pan-cancer analysis (green) as well as in breast (purple) and lung (orange) lineages chosen for downstream functional validation. Bars represent the mean, error bars the standard deviation of the posterior. c Depletion scores for CDKN1A ORFs across 17 independent screens, including breast (BRCA), ovarian (OV), neuroblastoma (NB), skin cutaneous melanoma (SKCM), lung adenocarcinoma (LUAD), Ewing sarcoma (EWS), medulloblastoma (MB) and prostate adenocarcinoma (PRAD) cell lines. The mean log-fold change in growth is shown as a line for each tumor type. d Lung and breast cancer cell lines chosen for functional validation based on their gene expression and DNA copy number profile on CCLE. e CDKN1A overexpression leads to a growth inhibition phenotype upon varying levels of overexpression. The mean and S.D. of three replicates are shown. Data was analyzed using two-way ANOVA.